NxStage Medical, Inc. Announces 2006 Chronic Therapy Scientific Advisory Board
LAWRENCE, Mass., April 5 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. , a medical device company that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease and acute kidney failure, announced today the formation of its 2006 Chronic Therapy Scientific Advisory Board. The establishment of this Scientific Advisory Board, comprised of well known and highly experienced physicians and researchers in the field of renal care, further demonstrates NxStage's commitment to advancing the clinical and scientific support for more frequent and home hemodialysis therapies.
NxStage's 2006 Chronic Therapy Scientific Advisory Board is a team of top dialysis thought leaders, from both academic and private practice, who bring significant expertise and knowledge of home hemodialysis, peritoneal dialysis, epidemiology, data analysis and dialysis kinetics. "We are extremely pleased to work with a group of physicians with such expertise, diversity of experience and commitment to home hemodialysis," said Mr. Jeffrey Burbank, NxStage's Chief Executive Officer. "We expect these members to have a significant impact on NxStage's movement towards transforming renal care and enhancing patient health, freedom and quality of life."
The company has appointed Alan R. Hull, M.D., F.A.C.P. as the chairman of the 2006 Chronic Therapy Scientific Advisory Board. Dr. Hull is the Chief Medical Advisor for NxStage Medical, Inc., and currently serves as the president of Renal Management, Inc.
"I am thrilled to be a part of such a skilled and highly knowledgeable group of physicians, who are committed to providing clinical and scientific insight into daily home hemodialysis. I'm also excited about our collaboration with NxStage, a company committed to receiving and responding to clinician input," said Dr. Hull. "With more frequent therapy, patients undergoing hemodialysis at home may experience not only clinical benefits, but also greater control over their treatment and maintenance of a more normal lifestyle."
Scientific Advisory Board members will serve for pre-determined terms so that new members with different perspectives can be rotated in periodically. Additional information on the 2006 Chronic Therapy Scientific Advisory Board members appears below.
Alan Collins, M.D., F.A.C.P., is Professor of Medicine at the University of Minnesota located in Minneapolis, MN. Currently the Director of Chronic Disease Research Group at the Minneapolis Medical Research Foundation, Dr. Collins brings extensive experience with epidemiology, as well as analytics and interpretation of USRDS data. Dr. Collins is also the current President-elect of the National Kidney Foundation.
Frederic Finkelstein, M.D., is Chief of Nephrology at the Hospital of St. Raphael in New Haven, CT and Clinical Professor of Medicine at Yale University. Dr. Finkelstein has extensive experience with home dialysis, particularly peritoneal dialysis, and is a physician at New Haven CAPD.
Joel Glickman, M.D., F.A.C.P., is Director of the Home Dialysis Program at the DaVita-Franklin Dialysis Center in Philadelphia and maintains a private practice with Pennsylvania Nephrology Associates in Philadelphia. He also serves as National Medical Consultant for PD and home hemodialysis for DaVita, and is Clinical Associate Professor of Medicine at the University of Pennsylvania School of Medicine. Dr. Glickman has developed significant experience with the NxStage chronic System in his home hemodialysis program. His program began using the NxStage System One in February 2005 and currently has over 20 patients using the NxStage System.
Bertrand Jaber, M.D., F.A.S.N., is Vice Chair of Medicine for Clinical Affairs at Caritas St. Elizabeth's Medical Center in Boston, MA and Associate Professor of Medicine at Tufts University School of Medicine. Dr. Jaber served as Co-Principal Investigator in NxStage's Hemofiltration study, which was conducted between 2002 and 2003. He is also a Principal Advisor in the NxStage FREEDOM (Following Rehabilitation, Economics, and Everyday Dialysis Outcome Measurements) study, an ongoing large, post-market observational study aimed at quantifying the clinical benefits and cost savings of daily hemodialysis therapy administered to Medicare patients with the NxStage System One versus conventional thrice-weekly hemodialysis.
Michael Kraus, M.D., is Associate Professor of Clinical Medicine and Clinical Chief for the Division of Nephrology at Indiana University Medical School in Indianapolis, IN. Dr. Kraus was Principle Investigator for NxStage's Home Sweet Home study which demonstrated similar safety and efficacy of the NxStage System One whether used in the home or the dialysis clinic setting. Dr. Kraus has significant experience with the NxStage System, having used the critical care System since March 2003 and the chronic System since November 2004. His program currently has over 30 chronic hemodialysis patients using the NxStage System One.
J. Kenneth Leypoldt, Ph.D., is Research Professor of Medicine in the Division of Nephrology at the University of Utah and VA Medical Center in Salt Lake City, Utah. Dr. Leypoldt has written for numerous scientific publications on kinetics and technology related to more frequent, shorter dialysis treatments.
James McCarthy, M.D., F.A.C.P., is Professor of Medicine for the Division of Nephrology and Hypertension at Mayo Clinic College of Medicine located in Rochester, MN. His current work includes study of the clinical and technical aspects of hemodialysis, as well as research into quality improvement and outcomes for chronic dialysis patients.
Brent Miller, M.D., is Associate Professor of Medicine and Director of Dialysis Home Modalities at the Washington University School of Medicine in St. Louis, MO. Dr. Miller brings experience with both peritoneal and hemodialysis, and his program currently has 10 patients using the NxStage System One for home daily hemodialysis.
John Moran, M.D. B.S., F.R.A.C.P., is Chief Scientific Officer and Director of Medical Research for Satellite Healthcare in San Francisco, CA. Prior to his current positions, Dr. Moran was Vice President of Clinical Development at Baxter Renal Division and Senior Vice President and Chief Medical Officer at Vasca, Inc. in Tewksbury, MA. Dr. Moran has experience with the NxStage chronic System going back to September 2004, and has over 45 patients currently using the NxStage System at five centers within the Satellite-Wellbound system.
About NxStage Medical
NxStage Medical, Inc. is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com.
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to the likely impact of the Chronic Scientific Advisory Board, NxStage's movement towards transforming renal care and enhancing patient health, freedom, and quality of life, and the results of the FREEDOM study. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements including market acceptance and demand for the NxStage's System One, growth in home hemodialysis and more frequent dialysis, and certain other factors that may affect future operating results and which are detailed in NxStage's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2005. We are under no obligation to (and expressly disclaim any obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Contact: For NxStage Jennifer Viera Schwartz Communications 781-684-0770 email@example.comNxStage Medical, Inc.
CONTACT: Jennifer Viera of Schwartz Communications for NxStage,+1-781-684-0770, firstname.lastname@example.org
Web site: http://www.nxstage.com/